SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Ada Lovelace — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientAda Lovelace
Date of birth1815-12-10
IdentifiersMRN HR-NI031-SYN-TD; SSN (made up) 000-31-6729
Document date1851-10-20
AuthorConstance Whitley-Adeyemi, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Twenty-week review a week after the sixth and last chemotherapy cycle: blood counts, thyroid on pembrolizumab, tapering morphine, mood and her work. [S]

History of Present Illness

Mrs. Lovelace returns a week after her sixth and last cycle of carboplatin and paclitaxel; pembrolizumab continues every three weeks. She has had no bleeding. Her average pain is 2 of 10, and she has used a breakthrough dose only twice in the past month. She would like to take less morphine. The tingling in her toes is unchanged. She feels a little more tired than usual but has no cold intolerance, constipation beyond her usual, weight gain, or palpitations. Her mood is better and she is working on new mathematical notes most mornings. [S]

ElementDetail
TreatmentSix cycles completed; pembrolizumab continues
PainAverage 2 of 10; two breakthrough doses in a month
NeuropathyMild, unchanged
Thyroid symptomsSlightly more tired; no cold intolerance or weight gain
WorkNew mathematical notes most mornings

Review of Systems

SystemResultFinding
ConstitutionalPositiveA little more tired; weight steady
EndocrineNegativeNo cold intolerance, hair or skin change beyond chemotherapy, or palpitations
NeurologicalPositiveMild toe tingling, unchanged
PsychiatricNegativeMood better; PHQ-9 5

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Opium tincture (100 mg/mL opium, equivalent to 10 mg/mL morphine), 0.5 mL by mouth four to six times a day as needed for pain0.5 mL four to six times a day as neededOral route1849-06-03 to 1851-06-02completedS
Morphine sulfate oral solution 2 mg/mL, 5 mg (2.5 mL by oral syringe) every 4 hours as needed for pain5 mg every 4 hours as neededOral route1851-06-02activeS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth every 12 hours; swallow wholeevery 12 hoursOral route1851-06-16 to 1851-10-20completedS
Morphine sulfate extended-release 15 mg tablet, one tablet by mouth at night, for two weeks, then stoponce at night for two weeks, then stopOral route1851-10-20activeS
Naloxone 4 mg nasal spray, one spray in a nostril for suspected opioid overdose; call 911one spray as needed for suspected overdose; repeat after 2 to 3 minutes if neededNasal route1851-06-02activeS
Senna 8.6 mg tablet, two tablets by mouth at nighttwo tablets at nightOral route1851-06-02activeS
Polyethylene glycol 3350, 17 g in water by mouth once or twice a dayonce daily, up to twice dailyOral route1851-06-02activeS
Acetaminophen 500 mg tablet, two tablets by mouth three times a day1 g three times a dayOral route1851-06-02activeS
Ferric carboxymaltose 750 mg intravenous infusion, two doses at the first two visits750 mg on two occasions two weeks apartIntravenous route1851-06-02 to 1851-06-17completedS
Pembrolizumab 200 mg intravenously every 3 weeksevery 3 weeksIntravenous route1851-06-30activeS
Carboplatin, dose to an AUC of 5 (650 mg), intravenously every 3 weeks for six cyclesevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Paclitaxel 175 mg/m2 (275 mg) intravenously every 3 weeks for six cycles, with premedicationevery 3 weeks for six cyclesIntravenous route1851-06-30 to 1851-10-13completedS
Ondansetron 8 mg tablet, one tablet by mouth twice a day for three days after each chemotherapy cycle, then as neededtwice a day for three days after each cycle, then as neededOral route1851-06-30activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1851-10-20Body height165cmS
1851-10-20Body weight54.4kgS
1851-10-20Body mass index (BMI) [Ratio]20kg/m2S
1851-10-20Systolic blood pressure114mm[Hg]S
1851-10-20Diastolic blood pressure72mm[Hg]S
1851-10-20Heart rate78/minS
1851-10-20Respiratory rate16/minS
1851-10-20Body temperature36.6CelS
1851-10-20Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1851-10-20Hemoglobin [Mass/volume] in Blood10.9g/dL12-15.5 g/dLLowS
1851-10-20Leukocytes [#/volume] in Blood by Automated count4.210*3/uL4-11 10*3/uLNormalS
1851-10-20Neutrophils [#/volume] in Blood by Automated count2.410*3/uL1.8-7.7 10*3/uLNormalS
1851-10-20Platelets [#/volume] in Blood by Automated count18810*3/uL150-400 10*3/uLNormalS
1851-10-20Creatinine [Mass/volume] in Serum or Plasma0.71mg/dL0.57-1 mg/dLNormalS
1851-10-20Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma24U/L7-35 U/LNormalS
1851-10-20Thyrotropin [Units/volume] in Serum or Plasma7.8m[IU]/L0.45-4.5 mIU/LHighS
1851-10-20Thyroxine (T4) free [Mass/volume] in Serum or Plasma1ng/dL0.8-1.8 ng/dLNormalS
1851-10-20Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1846)/1.73 sq M114mL/min/{1.73_m2}60 or moreNormalS
1851-10-20Pain severity - 0-10 verbal numeric rating [Score] - Reported2{score}S
1851-10-20Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 1851-10-20; see the Vital Signs section. [S]

SystemFinding
GeneralWell, alert; blood pressure 114/72, pulse 78, weight 54.4 kg
NeckNo thyroid enlargement or tenderness
NeurologicalReflexes normal; grade 1 sensory neuropathy at the toes

Problems

ProblemClinical statusVerificationCodeProvenance
Bleeding between periods and after intercourse, with heavier periods, a watery blood-stained discharge and a constant pelvic ache, for about five months; average pain 7 of 10 despite her opium tincture; a friable cervical mass found on examination and biopsied; cause not yet established at intakeresolvedconfirmed N93.8S — Synthetic presenting problem anchored to her documented final illness; superseded by the diagnosis at the second visit.
Iron deficiency anemia from chronic blood loss: hemoglobin 8.4 g/dL, mean cell volume 74 fL, ferritin 5 ng/mL, with tiredness and breathlessness on stairsactiveconfirmed D50.0S — Synthetic modern finding anchored to her documented final illness.
Adenocarcinoma of the endocervix, usual (HPV-associated) type, HPV 18 positive, FIGO 1843 stage IVB: a 5.2 cm tumor with left parametrial invasion, metastases to left pelvic and para-aortic lymph nodes, and bilateral lung metastases on MRI and PET-CT; PD-L1 combined positive score 5, mismatch repair proficient, HER2 1+; treated with palliative pelvic radiation for bleeding and carboplatin, paclitaxel and pembrolizumab, with specialist palliative care from diagnosisactiveconfirmed C53.0S — Synthetic modern diagnosis made at the second visit, anchored to her documented uterine cancer; the cervical site is a synthetic choice.
Cancer-related pelvic pain, nociceptive and visceral, from the cervical tumor and its left parametrial extensionactiveconfirmed G89.3S — Synthetic modern diagnosis made at the second visit.
Long-term prescribed opioid therapy: opium tincture for recurrent pelvic and abdominal pain for about two years, measured at times with a household spoon, converted at intake to measured oral morphine; no opioid use disorder on a DSM-5 assessment; naloxone suppliedactiveconfirmed Z79.891S — Synthetic modern history anchored to her documented laudanum and opium; not a claim about her real dosing.
Drug-induced constipation from long-acting morphine and ondansetron, a week after the first chemotherapy cycle: no bowel movement for five days, with bloating and cramping but passing wind, without vomiting; no bowel obstruction on examination; potassium and calcium normal; resolved with laxativesresolvedconfirmed K59.03S — Synthetic adverse drug effect; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryBlood count (hemoglobin, white cells, neutrophils, platelets)Before each chemotherapy cycle and at each visitCompleted todayHemoglobin 10.9 g/dL, white cells 4.2, neutrophils 2.4, platelets 188
LaboratoryCreatinine, eGFR and ALTBefore each cycleCompleted todayCreatinine 0.71 mg/dL, eGFR 114, ALT 24 U/L
LaboratoryTSH and free T4 on pembrolizumabBaseline, then every 6 weeksCompleted todayTSH 7.8 mIU/L, free T4 1.0 ng/dL, six weeks after the last check; subclinical; repeat in six weeks
ExaminationVaginal bleeding and transfusion needEvery visitCompleted todayNo bleeding
ExaminationImmune-related adverse effects: rash, diarrhea, cough, fatigueEvery visitCompleted todayMild tiredness only
ExaminationPeripheral neuropathy on paclitaxelWith taxane treatment and afterCompleted todayGrade 1, unchanged
ImagingRestaging CT of chest, abdomen and pelvisEvery 2 to 3 cycles during first-line therapy, then every 3 monthsDueAbout three months after the last CT, in six weeks
SurveyPain intensity (0 to 10) and functionEvery visitCompleted todayAverage 2 of 10
Medication safetyOpioid taper when pain improvesWhen pain is controlled after treatmentCompleted todayLong-acting morphine reduced to nightly for two weeks, then stopped
Medication safetyOpioid adverse effects: sedation, confusion, nauseaEvery visitCompleted todayNo sedation
Medication safetyBowel regimen and constipationEvery visitCompleted todayRegular
Medication safetyNaloxone, locked storage, one prescriber, prescription monitoring checkAt each opioid changeCompleted todayNaloxone in date; take-back advised
SurveyDepression screen (PHQ-9) and distressPeriodicallyCompleted todayPHQ-9 5
ReferralSpecialist palliative careOngoing alongside cancer treatmentUp to dateMonthly palliative care visits
Self-managementGoals-of-care conversationAt each restagingUp to dateRecorded six weeks ago; to revisit after the next CT

Goal progress:

Immunizations given today: Influenza vaccine, inactivated, trivalent; COVID-19 mRNA vaccine, current season; Recombinant zoster vaccine, dose 2 of 2; Hepatitis B vaccine, CpG-adjuvanted (two-dose series), dose 2 of 2 [S]

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer (2026); Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer (KEYNOTE-826; Colombo N, et al. N Engl J Med 2021;385:1856-1867) (2021); Palliative Care for Patients With Cancer: ASCO Guideline Update (Sanders JJ, et al. J Clin Oncol 2024;42:2336-2357) (2024); Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline (Paice JA, et al. J Clin Oncol 2023;41:914-930) (2023); CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (Dowell D, et al. MMWR Recomm Rep 2022;71(RR-3):1-95) (2022); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update (Schneider BJ, et al. J Clin Oncol 2021;39:4073-4126) (2021)

Follow-up: Telephone check in one week. Review after the restaging CT in about six weeks. [S]